Remdesivir for COVID-19 patients
GS Paper II: Issues relating to development and management of Social Sector or Services relating to Health, Education, Human Resources.
Context: Remdesivir is being seen as a potent therapy for COVID-19 patients in 127 countries across the globe, including India.
The list of 127 countries consist of nearly all low-income and lower middle-income countries as well as several upper middle and high-income countries that face significant obstacles to healthcare access.
Why is it in news?
Jubilant Life Science, through a subsidiary, has entered into a non-exclusive licensing agreement with Gilead Sciences Inc, to register, manufacture and sell Gilead’s Remdesivir, a potential therapy for COVID-19 in 127 countries.
- Under the agreement, Jubilant Generics, the subsidiary, will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production.
- This will enable expedited access of the medicine to COVID-19 patients upon approvals by regulatory authorities in the respective countries.
What else is to be known about Remdesivir for COVID-19?
- Remdesivir is a broad-spectrum antiviral medication developed by the United States biopharmaceutical company Gilead Sciences.
- Remdesivir was originally developed to treat hepatitis C and was then tested against Ebola virus disease and Marburg virus disease, but was ineffective for all of these viral infections.
- As of 2020, remdesivir is being tested as a specific treatment for recent coronavirus, and has been authorized for emergency use in the U.S. and approved for use in Japan for people with severe symptoms.
- It may shorten the time it takes to recover from the infection. Treatment is given by injection into a vein.
- An investigational anti-viral therapy developed by Gilead, Remdesivir received Emergency Use Authorisation (EUA) by the US Food and Drug Administration to treat coronavirus.
- The Authorisation will facilitate broader use of Remdesivir to treat hospitalised patients with severe COVID-19 disease.
PRELIMS Background Bites
Central Drugs Standard Control Organisation | India’s Drug Regulation Authority
- The Central Drugs Standard Control Organisation (CDSCO) is the national regulatory body for Indian pharmaceuticals and medical devices.
- It serves parallel function to the European Medicines Agency of the European Union, the PMDA of Japan, the Food and Drug Administration of the United States and the Medicines and Healthcare products Regulatory Agency of the United Kingdom.
- It is headquartered in New Delhi, India.
- Within the CDSCO, the Drug Controller General of India (DCGI) regulates pharmaceutical and medical devices, under the gamut of Ministry of Health and Family Welfare.
Subscribe to our newsletter!
INDIATHINKERS is now on TELEGRAM as ExamGuideUpsc. Join our Channel to get the latest posts updates and other important quiz and pdf materials.